Chapter 26 Selective Percutaneous Posterolateral Endoscopic Lumbar Nuclectomy
The three distinct mechanisms for pain relief by selective percutaneous posterolateral endoscopic lumbar discectomy are a manageable bulk decompression under direct endoscopic visualization and fluoroscope guidance, dilution of inflammatory peptides through continuous irrigation, and denervation of ingrown nerves by means of radiofrequency and laser (Fig. 26-1).
Selective chromoendoscopy (Table 26.1) in spine surgery is based on using the specific indicator (a blue color) of indigo carmine that is highly reactive with acidic extracellular matrix in degenerated nucleus pulposus. There is strong evidence for the usefulness of applying indigo carmine for selective endoscopic intervertebral nuclectomy in degenerated nucleus. However, there is no strict difference between normal aging and degeneration in the intervertebral disc (IVD), and an acidic condition of the IVD does not always indicate a pathologic condition. Removal of all blue-colored nucleus pulposus ensures the removal of all degenerated nucleus pulposus, whether or not the IVD is pathologically degraded. To remove the neural compression of herniated nucleus, decompression must become the primary purpose. Therefore, selective nuclectomy must be performed only when the targeted herniated nucleus turned blue in the posterior third of the IVD during chromoendoscopy.
Selective | Blue-stained degenerated acid nucleus pulposus |
Percutaneous | A small incision, not open |
Posterolateral | Minimization of muscle trauma, with passage through the intervertebral foramen |
Endoscopic | Under direct visualization |
Nuclectomy | Targeted third of posterior herniated nucleus under fluoroscopic guidance |
Indications
Selective percutaneous posterolateral endoscopic lumbar nuclectomy is indicated (1) in patients who are experiencing an intractable pain unresponsive to epidural steroid injection, to remove an inflammatory component of discogenic pain, and (2) for decompression of a compressed neural component (Box 26.1).
Complications
The informed consent discussion with the patient should include the following possible complications and their management (Table 26.2):
Potential Complication | Cause(s) | Management |
---|---|---|
Inability to access the involved area |